Biosurface Technologies Inc. (BioSET)Biosurface Technologies Inc. (BioSET) is a development stage medical technology company engaged in the development of synthetic growth factors which mimic the effect of naturally occurring growth factors, but which are much less expensive to produce and easier to incorporate into coatings for medical devices. The company has completed successful clinical trials in Canada evaluating a BMP-2 mimetic (B2A) product for both spine and ankle fusions. The FDA has approved a pivotal clinical trial for Prefix, the company’s lead product to be used in spinal fusion. BioSET also has a collaboration with Tornier to develop its FGF-2 mimetic (F2A) agent for orthopedic soft tissue repair.
The Vertical Group was a founding investor of BioSET. John E. Runnells was a member of its Board of Directors. |
Galil MedicalGalil Medical is a pioneer and leader in the market for cryotherapy systems utilized to treat prostate and kidney cancer as well as non-cancerous disorders such as uterine fibroids. The company's technology is based on the ability to freeze and ablate tissue in a procedure that is both precise and minimally invasive. Based in Yokneam, Israel, Galil has a direct sales organization in the United States and has world-wide sales exceeding $20 million.
The Vertical Group participated in a change of control and recapitalization financing for Galil Medical. Richard B. Emmitt was a member of its Board of Directors. |
IncumedIncumed is a medical device "incubator" committed to working with physicians, engineers, and other inventors with new product ideas that may not have the commercial profile required by large corporations or the venture capital community. Incumed partners with inventors and utilizes its experience and resources to maximize the commercial value of a new product idea.
The Vertical Group was Incumed's founding investor. Richard B. Emmitt and John E. Runnells are members of its Board of Directors. |
InPhenixInPhenix Corporation is a leading developer and manufacturer of optoelectronic devices for the medical, defense, and telecom markets. The Company's Super Light Emitting Diodes (SLEDs) are utilized in a variety of optical imaging systems for biomedical applications, and its customers include several leading manufacturers of ophthalmic and laboratory diagnostic instrumentation. The company is cash flow positive.
The Vertical Group was an early investor in InPhenix. Yue-Teh Jang is a member of its Board of Directors. |
https://www.vertical-group.com/current-portfolio.html |
Monteris MedicalMonteris Medical was founded in 1999 with the mission to create neurosurgical technology that, when used by neurosurgeons, would allow them to ablate (treat with lethal heat) brain lesions and brain tumors that may be difficult to approach via traditional methods.
Monteris Medical is focused on providing innovative MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. By combining the imaging power of Magnetic Resonance Imaging (MRI), advanced navigation software and Laser Interstitial Thermal Therapy (LITT), Monteris Medical has created a system to reach virtually any area of the brain. |
Meritage PharmaMeritage Pharma is committed to the development of prescription products based on safe and effective molecules for the treatment of gastrointestinal and atopic diseases. Meritage Pharma’s initial product candidate is intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the esophagus. The company is enrolling a clinical trial of oral budesonide suspension for the treatment of eosinophilic esophagitis. The trial is expected to be completed in 2014.
The Vertical Group was an early investor in Meritage |
OmadaOmada Health is a pioneer of digital health, and builds evidence-based programs for chronic disease prevention and health promotion. The company's flagship product, Prevent , is a 16-week program for individuals at risk for diabetes and is based entirely on the landmark Diabetes Prevention Program (DPP) clinical trial. The Omada Health founding team is an interdisciplinary group of technologists and entrepreneurs from Google, Amazon, IDEO, Stanford, and Harvard who are passionate about creating accessible technology to prevent disease.
USVP lead the series A investment in Omada. Tony Chou is a member of its Board of Directors. |
OncomedOncomed Pharmaceuticals, Inc. is a biopharmaceutical company that is developing drugs based on the newly discovered concept of 'cancer stem cells'. The company's scientific founders were among those responsible for first isolating such cancer stem cells, which appear to be the rare cells in tumors responsible for producing malignancy and tumor growth. In 2007 OncoMed and GlaxoSmithKline (“GSK”) formed a strategic alliance to develop cancer therapeutics based on the Company's cancer stem cell antibody technology. In 2010, Oncomed completed a second major collaboration partnership with Bayer Pharmaceuticals for development of antibodies in the Wnt pathway. The company retains rights to many additional drug development candidates and has the capital in place to finance the completion of thirteen major phase ll clinical trials by the end of 2016. Oncomed successfully completed its initial public offering in July 2013. The company received net proceeds of $83 million.
The Vertical Group participated in the founding venture round. Jack W. Lasersohn is the company’s lead Director. |
Outset MedicalOutset is a pioneering medical technology company that always puts the patient before the machine. The company's human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. And to achieve this goal, Outset has brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention.
Because Outset believes a dialysis machine should be as easy to use as an everyday consumer product, Tablo was designed with simplicity in mind. The Vertical Group participated in a Series A financing that was led by Warburg Pincus. Tony Chou is a member of the board of directors. |
ProteinSimpleProteinSimple (formally Cell Biosciences) is developing research tools for the biotechnology industry. The company has developed a novel instrument system that will improve both the throughput and accuracy of traditional protein detection assays currently performed using the 'western blot' system. The company is also ‘rolling up’smaller instrumentation companies in this space and has already completed a number of substantial acquisitions. A number of the acquired and internally developed technologies have the potential for breakout growth. We expect the company to exit 2013 with sales annualizing at $55 million.
The Vertical Group participated in a Series A financing. Jack W. Lasersohn is The Vertical Group contact. |
Remedy PharmaceuticalsRemedy Pharmaceuticals is an early-stage healthcare company dedicated to the development and commercialization of new drug treatments for victims of stroke. Remedy Pharmaceuticals' products use intellectual property licensed from the University of Maryland, Baltimore.
The company is an investment of Vertical GP-5 LLC. Tony Chou serves as the primary point of contact. |
Silk Road Medical
Silk Road Medical is developing a novel endovascular approach to treating neurovascular disease. It is currently in the process of enrolling a clinical trial and is also expanding the use of its approach.
The Vertical Group incubated Silk Road Medical. Warburg Pincus invested in the company in 2011. |
Singluar BIOSingularBIO is a development stage company with a disruptive platform for diagnostics testing. SingularBIO’s technology will allow cost effective, high precision diagnostic tests in the era of personalized medicine.
In 2013 the Vertical Group invested in the company. Tony Chou is a member of the board of directors. |
Tepha, Inc.
Tepha, Inc. is a development stage medical device company engaged in utilizing unique and proprietary biomaterials derived from a class of polymers known as PHAs (polyhydroxyalkanoates). Relative to conventional medical grade polymers, the Tepha PHA-derived materials are distinguished by their elasticity, flexibility, and non-acidic, "cell friendly" biodegradation. This profile positions the TephaFLEX and TephELAST polymers as ideal materials for medical devices of the future, and especially those devices emerging from the rapidly expanding field of tissue engineering. Tepha received its first FDA 510(k) release for a PHA polymer derived device in 2007. The company's commercial partners include Aesculap, ENTrigue Surgical, Lifecell, NMT Medical, Tornier, and a NYSE-listed leader in the hernia repair market.
The Vertical Group was the lead investor in Tepha at the time of its spin-off from its sister company, Metabolix, Inc. Richard B. Emmitt and Edward M. Giles are members of Tepha's Board of Directors. |
TetraLogic PharmaceuticalsTetraLogic Pharmaceuticals discovers and develops important drugs to treat cancer. TetraLogic's founding scientists, Drs. George McLendon and Yigong Shi, at Princeton University, developed TetraLogic's core technology, called 'Smac mimetics', which enables drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells. The company initiated clinical studies during 2010 with very promising early results. The company also completed a major Series C equity financing led by new investor Clarus Venture Partners.
The Vertical Group participated in the company's Series B financing in 2006 and Series C financing in 2010. Jack Lasersohn was a member of its Board of Directors from 2006-2010 and became a board observer in 2010 following the Series C financing. |
TornierTornier is a global orthopedic company and a leader in the market for shoulder and extremity joint replacement systems. Based in Grenoble, France, Tornier has been a respected orthopedic industry pioneer since its founding during the 1940's. During the 1990's, Tornier's close collaboration with prominent surgeons led to the commercialization of the AEQUALIS shoulder and SALTO ankle product lines. During 2007 and 2008, Tornier completed four acquisitions and four corporate partnerships to expand its line of upper and lower extremity product lines and also to enter the sports/arthroscopy market. The Company's annual sales are approximately $200 million.
In July of 2006 The Vertical Group and its co-investor, Warburg Pincus, purchased a controlling interest in Tornier. Richard Emmitt is a member of its Board of Directors. |
ViaCyte
ViaCyte is a pioneer in the field of islet cell transplantation for the treatment of diabetes. The company's cellular encapsulation and cell culture technology may lead to an alternative to life-long insulin injection therapy for millions of diabetics. Its VC-01 combination product has the potential to transform the way patients with type 1 diabetes manage their disease, and could also be an important treatment for insulin-dependent type 2 diabetes. ViaCyte has strategic partnerships with Becton Dickenson and SurModics.
The Vertical Group participated in the founding financing round for the Company. Jack W. Lasersohn is the Vertical Group contact. |